Repare Therapeutics Inc. (RPTX)
NASDAQ$1.1-0.02 (-1.79%)
Market Cap
$47.61M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
819 of 924
Rank in Industry
466 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
RPTX Insider Trading Activity
RPTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $101,063 | 20 | 100 |
Related Transactions
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | 0 | $0 | 5 | $10,303 | $-10,303 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER | 0 | $0 | 5 | $10,718 | $-10,718 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 0 | $0 | 5 | $19,007 | $-19,007 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO | 0 | $0 | 5 | $61,035 | $-61,035 |
About Repare Therapeutics Inc.
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related …
Insider Activity of Repare Therapeutics Inc.
Over the last 12 months, insiders at Repare Therapeutics Inc. have bought $0 and sold $101,063 worth of Repare Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Repare Therapeutics Inc. have bought $40.13M and sold $25.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 295,745 shares for transaction amount of $1.59M was made by BVF PARTNERS L P/IL (10 percent owner) on 2023‑11‑16.
List of Insider Buy and Sell Transactions, Repare Therapeutics Inc.
| 2024-04-01 | Sale | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | 300 0.0007% | $4.66 | $1,398 | -30.74% | |
| 2024-04-01 | Sale | Segal Lloyd Mitchell | PRESIDENT AND CEO | 2,491 0.0058% | $4.63 | $11,533 | -30.74% | |
| 2024-04-01 | Sale | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | 410 0.001% | $4.66 | $1,911 | -30.74% | |
| 2024-04-01 | Sale | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 789 0.0018% | $4.61 | $3,637 | -30.74% | |
| 2024-03-28 | Sale | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.64 | $2,320 | -30.79% | |
| 2024-03-28 | Sale | Segal Lloyd Mitchell | PRESIDENT AND CEO | 2,650 0.0062% | $4.62 | $12,243 | -30.79% | |
| 2024-03-28 | Sale | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.64 | $2,088 | -30.79% | |
| 2024-03-28 | Sale | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 825 0.0019% | $4.62 | $3,812 | -30.79% | |
| 2024-03-27 | Sale | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.62 | $2,310 | -30.19% | |
| 2024-03-27 | Sale | Segal Lloyd Mitchell | PRESIDENT AND CEO | 2,650 0.0062% | $4.63 | $12,270 | -30.19% | |
| 2024-03-27 | Sale | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.62 | $2,079 | -30.19% | |
| 2024-03-27 | Sale | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 825 0.0019% | $4.62 | $3,812 | -30.19% | |
| 2024-03-26 | Sale | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.60 | $2,300 | -28.04% | |
| 2024-03-26 | Sale | Segal Lloyd Mitchell | PRESIDENT AND CEO | 2,650 0.0064% | $4.64 | $12,296 | -28.04% | |
| 2024-03-26 | Sale | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.61 | $2,075 | -28.04% | |
| 2024-03-26 | Sale | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 825 0.002% | $4.60 | $3,795 | -28.04% | |
| 2024-03-25 | Sale | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | 500 0.0012% | $4.78 | $2,390 | -31.51% | |
| 2024-03-25 | Sale | Segal Lloyd Mitchell | PRESIDENT AND CEO | 2,650 0.0063% | $4.79 | $12,694 | -31.51% | |
| 2024-03-25 | Sale | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | 450 0.0011% | $4.78 | $2,151 | -31.51% | |
| 2024-03-25 | Sale | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 825 0.002% | $4.79 | $3,952 | -31.51% |
Total: 154
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Segal Lloyd Mitchell | PRESIDENT AND CEO | 107558 0.253% | $120,464.96 | 1 | 13 | <0.0001% |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER | 44775 0.1053% | $50,148.00 | 1 | 5 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 5309432 12.4896% | $5.95M | 4 | 0 | <0.0001% |
| LAMPERT MARK N | 4443423 10.4525% | $4.98M | 3 | 0 | +11.32% | |
| GADICKE ANSBERT | 10 percent owner | 3882485 9.133% | $4.35M | 1 | 30 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$1,695,621 | 55 | 17.90% | $43.58M | |
$15,956,086 | 53 | 5.33% | $44.72M | |
$81,638,324 | 48 | 7.58% | $53.53M | |
$18,274,594 | 22 | -26.07% | $47.82M | |
Repare Therapeutics Inc. (RPTX) | $160,539,875 | 21 | -6.57% | $47.61M |
RPTX Institutional Investors: Active Positions
| Increased Positions | 21 | +28% | 892,565 | +2.76% |
| Decreased Positions | 30 | -40% | 3M | -8.15% |
| New Positions | 9 | New | 235,544 | New |
| Sold Out Positions | 11 | Sold Out | 443,002 | Sold Out |
| Total Postitions | 66 | -12% | 31M | -5.4% |
RPTX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bvf Inc/Il | $12,194.00 | 24.03% | 10.33M | 0 | 0% | 2024-12-31 |
| Blue Owl Capital Holdings Lp | $4,064.00 | 8.01% | 3.44M | +71,160 | +2.11% | 2024-12-31 |
| Orbimed Advisors Llc | $3,921.00 | 7.73% | 3.32M | 0 | 0% | 2024-12-31 |
| Versant Venture Management, Llc | $3,123.00 | 6.16% | 2.65M | 0 | 0% | 2024-12-31 |
| Ark Investment Management Llc | $2,360.00 | 4.65% | 2M | -509,740 | -20.31% | 2024-12-31 |
| Redmile Group, Llc | $2,261.00 | 4.46% | 1.92M | -26,466 | -1.36% | 2024-12-31 |
| Mpm Asset Management Llc | $1,987.00 | 3.92% | 1.68M | -558,929 | -24.92% | 2024-12-31 |
| Aquilo Capital Management, Llc | $1,527.00 | 3.01% | 1.29M | +304,351 | +30.76% | 2024-12-31 |
| Mpm Bioimpact Llc | $1,453.00 | 2.86% | 1.23M | -408,695 | -24.92% | 2024-12-31 |
| Acadian Asset Management Llc | $557.00 | 1.1% | 472,102 | +24,509 | +5.48% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.